These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 15585838)

  • 1. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells.
    Salcedo R; Stauffer JK; Lincoln E; Back TC; Hixon JA; Hahn C; Shafer-Weaver K; Malyguine A; Kastelein R; Wigginton JM
    J Immunol; 2004 Dec; 173(12):7170-82. PubMed ID: 15585838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow.
    Salcedo R; Hixon JA; Stauffer JK; Jalah R; Brooks AD; Khan T; Dai RM; Scheetz L; Lincoln E; Back TC; Powell D; Hurwitz AA; Sayers TJ; Kastelein R; Pavlakis GN; Felber BK; Trinchieri G; Wigginton JM
    J Immunol; 2009 Apr; 182(7):4328-38. PubMed ID: 19299733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2.
    Jackaman C; Bundell CS; Kinnear BF; Smith AM; Filion P; van Hagen D; Robinson BW; Nelson DJ
    J Immunol; 2003 Nov; 171(10):5051-63. PubMed ID: 14607902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular mechanisms of interleukin-12-mediated neuroblastoma regression.
    Redlinger RE; Shimizu T; Remy T; Alber S; Watkins SC; Barksdale EM
    J Pediatr Surg; 2003 Feb; 38(2):199-204. PubMed ID: 12596103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IL-21 induces tumor rejection by specific CTL and IFN-gamma-dependent CXC chemokines in syngeneic mice.
    Di Carlo E; Comes A; Orengo AM; Rosso O; Meazza R; Musiani P; Colombo MP; Ferrini S
    J Immunol; 2004 Feb; 172(3):1540-7. PubMed ID: 14734732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic modulation of Akt activity and antitumor efficacy of interleukin-12 against orthotopic murine neuroblastoma.
    Khan T; Hixon JA; Stauffer JK; Lincoln E; Back TC; Brenner J; Lockett S; Nagashima K; Powell D; Wigginton JM
    J Natl Cancer Inst; 2006 Feb; 98(3):190-202. PubMed ID: 16449679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibition to maximize the apoptotic potential of cytokine therapy for murine neuroblastoma tumors.
    Khan T; Stauffer JK; Williams R; Hixon JA; Salcedo R; Lincoln E; Back TC; Powell D; Lockett S; Arnold AC; Sayers TJ; Wigginton JM
    J Immunol; 2006 May; 176(10):6302-12. PubMed ID: 16670342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synergistic interleukin-18 and low-dose interleukin-2 promote regression of established murine neuroblastoma in vivo.
    Redlinger RE; Mailliard RB; Lotze MT; Barksdale EM
    J Pediatr Surg; 2003 Mar; 38(3):301-7; discussion 301-7. PubMed ID: 12632339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transient depletion of CD4(+) T cells augments IL-21-based immunotherapy of disseminated neuroblastoma in syngeneic mice.
    Croce M; Corrias MV; Orengo AM; Brizzolara A; Carlini B; Borghi M; Rigo V; Pistoia V; Ferrini S
    Int J Cancer; 2010 Sep; 127(5):1141-50. PubMed ID: 20039320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor and antimetastatic activity of IL-23.
    Lo CH; Lee SC; Wu PY; Pan WY; Su J; Cheng CW; Roffler SR; Chiang BL; Lee CN; Wu CW; Tao MH
    J Immunol; 2003 Jul; 171(2):600-7. PubMed ID: 12847224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes.
    Martinotti A; Stoppacciaro A; Vagliani M; Melani C; Spreafico F; Wysocka M; Parmiani G; Trinchieri G; Colombo MP
    Eur J Immunol; 1995 Jan; 25(1):137-46. PubMed ID: 7843224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chronic immune therapy induces a progressive increase in intratumoral T suppressor activity and a concurrent loss of tumor-specific CD8+ T effectors in her-2/neu transgenic mice bearing advanced spontaneous tumors.
    Nair RE; Kilinc MO; Jones SA; Egilmez NK
    J Immunol; 2006 Jun; 176(12):7325-34. PubMed ID: 16751376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversing tumor immune suppression with intratumoral IL-12: activation of tumor-associated T effector/memory cells, induction of T suppressor apoptosis, and infiltration of CD8+ T effectors.
    Kilinc MO; Aulakh KS; Nair RE; Jones SA; Alard P; Kosiewicz MM; Egilmez NK
    J Immunol; 2006 Nov; 177(10):6962-73. PubMed ID: 17082611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor-specific Tc1, but not Tc2, cells deliver protective antitumor immunity.
    Kemp RA; Ronchese F
    J Immunol; 2001 Dec; 167(11):6497-502. PubMed ID: 11714817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of protective immune responses against NXS2 neuroblastoma challenge in mice by immunotherapy with GD2 mimotope vaccine and IL-15 and IL-21 gene delivery.
    Kowalczyk A; Wierzbicki A; Gil M; Bambach B; Kaneko Y; Rokita H; Repasky E; Fenstermaker R; Brecher M; Ciesielski M; Kozbor D
    Cancer Immunol Immunother; 2007 Sep; 56(9):1443-58. PubMed ID: 17597331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful adoptive immunotherapy of murine poorly immunogenic tumor with specific effector cells generated from gene-modified tumor-primed lymph node cells.
    Tanaka H; Yoshizawa H; Yamaguchi Y; Ito K; Kagamu H; Suzuki E; Gejyo F; Hamada H; Arakawa M
    J Immunol; 1999 Mar; 162(6):3574-82. PubMed ID: 10092816
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IFN-gamma-inducing factor/IL-18 administration mediates IFN-gamma- and IL-12-independent antitumor effects.
    Osaki T; Péron JM; Cai Q; Okamura H; Robbins PD; Kurimoto M; Lotze MT; Tahara H
    J Immunol; 1998 Feb; 160(4):1742-9. PubMed ID: 9469432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD25+ regulatory T cell depletion augments immunotherapy of micrometastases by an IL-21-secreting cellular vaccine.
    Comes A; Rosso O; Orengo AM; Di Carlo E; Sorrentino C; Meazza R; Piazza T; Valzasina B; Nanni P; Colombo MP; Ferrini S
    J Immunol; 2006 Feb; 176(3):1750-8. PubMed ID: 16424205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral interleukin-21 increases antitumor immunity, tumor-infiltrating CD8+ T-cell density and activity, and enlarges draining lymph nodes.
    Søndergaard H; Galsgaard ED; Bartholomaeussen M; Straten PT; Odum N; Skak K
    J Immunother; 2010 Apr; 33(3):236-49. PubMed ID: 20445344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.